Key result
Aptamer L44 specifically detected circulating Trypanosoma cruzi biomarkers in the plasma of infected mice during both acute (7 to 28 days) and chronic (55 to 230 days) phases of infection.
An aptamer-based assay can specifically detect circulating T. cruzi biomarkers in both acute and chronic phases of infection in a mouse model, offering a potential non-PCR, non-serological diagnostic tool for Chagas disease.
Urine TESA antigen detection may enable noninvasive congenital Chagas diagnosis; leaves open larger prospective validation before clinical adoption.
Chagas disease affects about 5 million people across the world. The etiological agent, the intracellular parasite Trypanosoma cruzi (T. cruzi), can be diagnosed using microscopy, serology or PCR based assays. However, each of these methods has their limitations regarding sensitivity and specificity, and thus to complement these existing diagnostic methods, alternate assays need to be developed. It is well documented that several parasite proteins called T. cruzi Excreted Secreted Antigens (TESA), are released into the blood of an infected host. These circulating parasite antigens could thus be used as highly specific biomarkers of T. cruzi infection. In this study, we have demonstrated that, using a SELEx based approach, parasite specific ligands called aptamers, can be used to detect TESA in the plasma of T. cruzi infected mice. An Enzyme Linked Aptamer (ELA) assay, similar to ELISA, was developed using biotinylated aptamers to demonstrate that these RNA ligands could interact with parasite targets. Aptamer L44 (Apt-L44) showed significant and specific binding to TESA as well as T. cruzi trypomastigote extract and not to host proteins or proteins of Leishmania donovani, a related trypanosomatid parasite. Our result also demonstrated that the target of Apt-L44 is conserved in three different strains of T. cruzi. In mice infected with T. cruzi, Apt-L44 demonstrated a significantly higher level of binding compared to non-infected mice suggesting that it could detect a biomarker of T. cruzi infection. Additionally, Apt-L44 could detect these circulating biomarkers in both the acute phase, from 7 to 28 days post infection, and in the chronic phase, from 55 to 230 days post infection. Our results show that Apt-L44 could thus be used in a qualitative ELA assay to detect biomarkers of Chagas disease.
No takes yet. Share an insight, caveat, or question.
Nagarkatti et al. (2014) studied Chagas disease (Trypanosoma cruzi infection). Aptamer L44 (Apt-L44) Enzyme Linked Aptamer (ELA) assay vs. Non-infected mice / scrambled aptamer was evaluated on Detection of T. cruzi excreted secreted antigens (TESA) in plasma. Aptamer L44 specifically detected circulating Trypanosoma cruzi biomarkers in the plasma of infected mice during both acute (7 to 28 days) and chronic (55 to 230 days) phases of infection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: